Targeting gut health has been found to be the latest weapon in the fight against prostate cancer. The results of the latest cancer nutritional intervention study were published in the medical Journal European Urology Oncology has highlighted the importance of strategies to improve the profile of friendly bacteria in our gut. This, is now the largest, comprehensive evaluation of the most up-to-date dietary strategy in for this disease.
Researchers found the study slowed PSA progression and also improved waterworks symptoms and erectile function. In addition, this is the World’s first double blind RCT to show that a probiotic, Yourgutplus, aiming to improve gut health, further reduced PSA progression, improved overall inflammation and grip strength (markers of longevity).
This trial provides essential scientific evidence for health professionals and practical guidance for people with cancer, interested in empowering themselves with the most effective strategies to improve their well-being and help alleviate the toxicities of hormonal, radiotherapy or surgical treatments. Men who stopped all other supplements and took 2 capsules each supplement a day had:
- A 44% slower rate prostate cancer progression measured by PSA
- MRI disease correlated with PSA & stabilised or shrunk in 91%
- A 25% improved urinary symptoms
- A 11% improvement in erectile function
- Reduced blood markers of systemic inflammation
- Enhanced grip strength and other markers of longevity
.
Yourgutplus, blends non-histamine inducing, non-diary, lactobacillus bacterial strains, combined with inulin from chicory, and vitamin D. It was previously evaluated and found to be beneficial in the UK national COVID nutritional intervention study and was chosen for the current covid vaccine support study – so has an excellent safety record.
Rational for the Study: Existing research, shows that phytochemicals intake and probiotics work in synergy to improve gut health, reduce inflammation in the body and has numerous other potential benefits not only for cancer but symptoms related to treatments Laboratory studies have already shown that manipulating gut bacteria can slow prostate cancer progression but until now, no clinical studies in men, up to now, had evaluated combining phytochemicals with probiotics.
High safety profile: As both these capsules were specifically made for national medical trials the ethical committee insisted on a level of quality assurance unprecedented in supplement manufacturing.
In this double blind RCT, men with early but progressive prostate cancer were given these nutritional interventions before considering treatments such as radiotherapy surgery, or hormone therapies, which have significant risks and toxicities that impact quality of life. 
None of the men in the study were taking any other supplements treatments for their prostate cancer.
Changing in underlying disease; Unique for a nutritional trial, was a finding that MRI scans taken before and after the interventions supported the PSA findings. In the combined group, disease on MRI actually reduced in size in 7% and stabilised in 84% of other men – this highlights that this intervention improves underlying disease not just PSA levels.
In conclusion:
This trial highlights the most up-to-date, comprehensively researched supplement available over the counter. It’s acclaimed scientific evaluation, not only significantly slowed PSA progression to a higher degree than previously reported, but for the first time it, also improved urinary symptoms and erectile function. This is the World’s first double blind RCT to demonstrate that a probiotic intervention, Yourgutplus, aiming to improve gut health, further reduced PSA progression, reduced longevity markers of inflammation and improved grip strength. This combination has been choice for a major intervention study in Women (see below) and further trials are planned evaluating their role for enhancing sports performance, strength and longevity.
Source details:
Abstract: Pubmed
Read full paper: European Urology Oncology Thomas R, Kenfield S, Williams M, Newton RU, Mitra A, Frazili Z Oct 2025